NCT00116168 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

July 31, 2006

Conditions

Healthy

Interventions

BIOLOGICAL

MEDI-528 0.3 mg/kg

MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose

BIOLOGICAL

MEDI-528 1 mg/kg

MEDI-528 (1 mg/kg) administered as a single, SC dose

BIOLOGICAL

MEDI-528 3 mg/kg

MEDI-528 (3 mg/kg) administered as a single, SC dose

BIOLOGICAL

MEDI-528 9 mg/kg

MEDI-528 (9 mg/kg) administered as a single, SC dose

Trial Locations (2)

MDS Pharma Services, Lincoln

MDS Pharma Services, New Orleans